Good day, and welcome to the Bruker's Second Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Justin Ward, Senior Director of Investor Relations and Corporate Development. Please go ahead.

Thank you. Good afternoon. I would like to welcome everyone to Bruker Corporation's Second Quarter 2022 Earnings Conference Call. My name is Justin Ward, and I am Bruker's Senior Director of Investor Relations and Corporate Development. Joining me on today's call are Frank Laukien, our President and CEO; and Gerald Herman, our Executive Vice President and CFO. In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. During today's call, we will be highlighting non-GAAP financial information. Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release and are posted on our website at ir.bruker.com. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on slide 2 of the presentation. During this conference call, we will make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to geopolitical and energy risks, the COVID-19 pandemic and supply chain, logistics and inflation challenges. The company's actual results may differ materially from such statements. Factors that might cause such differences include, but are not limited to, those discussed in today's earnings release and in our Form 10-K for the period ending December 31, 2021, as – and as updated by our other SEC filings, which are available on our website and on the SEC's website. Also, please note that, the following information is based on current business conditions and to our outlook as of today, August 3, 2022. We do not intend to update our forward-looking statements based on new information, future events or for other reasons, except as may be required by law, prior to the release of our third quarter 2022 financial results expected in early November 2022. You should not rely on these forward-looking statements as necessarily representing our views or outlook as of any other date after today. We will begin today's call with Frank providing an overview of our business progress. Gerald will then cover the financials for the second quarter and first half of 2022 in more detail and share updated fiscal year 2022 financial outlook. Now, I'd like to turn the call over to Bruker's CEO, Frank Laukien.

Thank you, Justin. Good afternoon, everyone, and thank you for joining us on today's second quarter 2022 earnings call. Turning to our slide 4, in the second quarter of 2022, Bruker delivered robust bookings growth with organic bookings growth again outpacing organic revenue growth. In the second quarter, we launched several compelling product innovations across our portfolio and our strong organic revenue growth of 8.8% was 160 bps above consensus. The solid performance came despite operational headwinds from significant supply chain and logistics delays, lockdowns in China, and the conflict in Europe. We again saw excellent demand for our differentiated, high-value scientific instruments and life science solutions, as evidenced by the strong momentum in organic bookings and revenue growth. For the second quarter of 2022, our Bruker Scientific Instruments or BSI segment, organic bookings were up double digits percentages year-over-year. And our BSI book-to-bill ratio remained greater than 1%. Finally, our BSI backlog remains very high. Bruker's second quarter 2022 reported revenues increased 3.1% year-over-year to $588.4 million, despite a strong FX headwind of minus 7.3%. On an organic basis, revenues increased 8.8%, which included 8.1% organic growth in BSI and 15.1% at BEST, net of intercompany eliminations, while growth from acquisitions added 1.6%. This implies constant exchange rate growth of 10.4% year-over-year. Our second quarter 2022 non-GAAP gross margin increased 180 bps year-over-year to 51.8%, while non-GAAP operating margin was 16.6%, a decrease of 70 bps year-over-year. Our gross margin expansion, despite inflation headwinds, is clearly benefiting from our Project Accelerate 2.0 margin mix as well as from volume leverage and currency tailwinds. In the second quarter, gross profit margin expansion was more than offset by our planned Project Accelerate 2.0, operating expense, OpEx investments in Commercial and R& D capabilities. In the second quarter of 2022, Bruker reported…

Thank you, Frank, and thanks, everyone, for joining us today. I'm pleased to provide some more detail on Bruker's second quarter 2022 financial performance starting on slide 11. In the second quarter of 2022, Bruker's reported revenue increased 3.1% to approximately $588 million, which reflects an organic revenue increase of 8.8% year-over-year. We reported GAAP EPS of $0.33 per share compared to $0.38 in the second quarter of 2021. On a non-GAAP basis, Q2 2022 EPS was $0.45 per share, an increase of 2.3% from the $0.44 in the second quarter of 2021. Our Q2 2022 non-GAAP operating income decreased 1.1% and our non-GAAP operating margin decreased 70 basis points year-over-year to 16.6%, with expanding gross margins more than offset by our planned Project Accelerate 2.0 investments. We finished the second quarter with cash, cash equivalents and short-term investments of approximately $723 million. During the quarter, we used cash to ramp selected Project Accelerate 2.0 investments, fund capital expenditures, complete several key inorganic investments in strategically relevant technologies, and fund share repurchases. You may recall that in May 2021, our Board approved a two-year share repurchase authorization up to $500 million through May of 2023. In the second quarter of 2022, we repurchased nearly 1 million shares for approximately $16 million and year-to-date, we repurchased 2.6 million shares for approximately $166 million. As a reminder, in the full year of 2021, our repurchases totalled 2.1 million shares for approximately $153 million. We used $44.4 million of operating cash in the second quarter of 2022, largely to build inventories for our planned revenue ramp in the second half of the year as well as to protect against supply chain risks. Operating cash flow was also impacted by the timing of tax payments and customer advances. Our capital expenditure investments were $17.9…

hank you, Gerald. I'd now like to turn the call over to the operator to begin the Q&A portion of the call. [Operator Instructions]

Thank you. We will now begin the question-and-answer session. [Operator Instructions] Our first question comes from Derik De Bruin of Bank of America Merrill Lynch. Please go ahead.

Hey, guys. This is Mike Ryskin on for Derik. I got a quick one on the updated guide and then a follow-up. First, on the guidance, I want to make sure I got this right. So it seems like the biggest change in the guide or really, the main change in the guide is the FX assumption is now 2.5 points higher because organic is unchanged. M&A is unchanged and your margin guidance unchanged. So I'm just wondering, how are you able to maintain the adjusted EPS guide? Is there something in the nonoperating lines that we're missing? Or is this just some rounding in the numbers somewhere in terms of higher end of the range, lower end of the range? Just given the 2.5 points more reported revenue headwind, you would think that EPS will be impacted as well.

Yeah. So it's Gerald here. So first of all, your assumption is correct. We are only modifying the foreign exchange element to the guide. The other elements, both organic revenue growth and non-GAAP EPS we're holding, reiterating those. So that's the first part of your question, I think. On the second part, yes, we obviously are facing some cost pressures on a number of fronts, including you've heard some of the story around supply chain challenges. But fundamentally, we continue to believe that our organic revenue numbers are solid, and we're quite comfortable with that. And on the EPS side, we're continuing to post solid gross margin activity through two quarters now. We've seen excellent OpEx management, I think, over those two quarters, and we're pretty comfortable on where we are at the EPS line given that.

Okay. All right. And then for the follow-up, I guess, on the book-to-bill comments and on the backlog, you continue to have really positive commentary on book-to-bill over 1.1, strong demand across most of the business. Could you give us a little bit of clarity on backlog conversion? When do you think some of those orders are going to be able to convert to revenues? Can you just sort of walk us through how that's going to flow through the business?

Well, as is typical for us, Mike, the second half tends to be stronger in terms of revenue and in terms of margins than the first half. That's our typical seasonality. We expect that. As you just heard, Q3 will not be as strong. We think Q4 will be stronger in helping us catch up. So and I mean this isn't - backlog conversion isn't going to be done. I mean, we always carry backlog, but it's not going to be normalized yet this year, as I think supply chain and logistics issues still prevail and are out there certainly for the remainder of this year. Some of that backlog, we expect to some of that may - be somewhat unusually high backlog we also expect to carry into next year.

Okay. Thanks.

The next question comes from Puneet Souda of SVB Securities. Please go ahead.

Frank, thanks for and Gerald, thanks for taking the question. So first one, I just wanted to -- I didn't hear on China. I just want to see if you can quantify that, what you saw there? And as you talked about the EPS line impact, I'm just sort of trying to understand from an op margin perspective, and you have sizable operations in Germany, are you expecting any challenges there in terms of the impact from energy and such? Some companies -- your peer companies have pointed that out, so I just wanted to check on that geographically as well.

If I may, Puneet, it's Gerald. I'll take the first part of your question regarding China and Frank can talk more intelligently about German situation. So with respect to China, so a very solid quarter for us in terms of revenue performance, despite a lot of the China lockdowns. I would say, the teams performed extremely well from the logistics perspective under challenging conditions. We saw a little softness in the order performance in China in the second quarter, but I don't read too much into that. We had very strong performance in the first quarter. So, what we understand on the ground is that things have opened up or are beginning to open up. There's still some challenges there, but our expectation is that, that will improve over time as we execute further into the second half of the year. We are anticipating logistics are going to improve there. And certainly, we've got a lot of backlog to be able to execute on for the second half of the year.

And with EPS, I think we just -- I think we were prudent in the way we guided for the year, and that's, I think we can -- that's why we continue to feel comfortable with our margin expansion and EPS guidance. As to Germany, I mean, there are some additional risks now. Europe has some additional energy risks and gas risks. It's all well known. First of all, we, at Bruker, really don't have any significant processes that use natural gas. So this is not a primary problem for us. Of course, there's other companies in metallurgy or in chemistry or et cetera, that use gas. So it's -- it could conceivably there is therefore a risk for increasing supply chain problems in certain areas, perhaps in the second or perhaps into next year, but it's not a direct primary risk for Bruker. In terms of energy or electricity rationing, we're not a heavy user, but of course, we need continuous power. So there is an incremental risk. We are, of course, saving on energy, like everybody else in Europe and in Germany, in particular. We are taking the prudent steps that we can take. And presently, most of our German factory managers do not anticipate any energy rationing or rolling blackouts or anything like that for -- even for this winter, but there is a risk, of course, not so different from what we had due to fires in California sometime -- some years ago. But there's some additional energy risks in Europe. And we have anticipated the inflation risk. Energy costs are certainly going up, although much of that is buffered or some of that is buffered by government, quite honestly, who are protecting consumers and even industry to some extent. But it remains a very dynamic environment between pandemic and supply chain challenges and now additional supply chain. Second tier supply chain and energy risks in Europe. We acknowledge they exist. We're not primarily affected, but we're keeping an eye on it. And of course, we're doing lots of contingency and other planning to manage through that.

Got it. That's very helpful, Frank. And just one on Ascend EVO, the 1.0 gigahertz, three orders that you had, one from Riken. So when do you think you can deliver those? And should we now assume three to four ultra-high frequency NMRs being ordered instead of the three to four being maybe a larger number for 2023, given these order -- given the current order book?

Good question and with some insight, of course, we now, of course, that gives us more capacity, right? The two-story, 1.1, 1.2 gigahertz systems, we have a certain capacity for those. The capacity for the 1.0 gigahertz is almost separate in addition. So in many ways, we've more than doubled our capacity in principle. So that doesn't have an effect yet on 2022, and we're not going to project 2023, '24 right now, but it does help us to have essentially two lines, the two-story magnets and the four Calvin single-story magnets. And we are just delighted that now early on, there's been some interest and kind of showing a, going into Asia Pacific or in this case, into Japan for biological research. And then if a country like Spain needs two of those, well, there are very many other countries or larger universities, or even high-end biopharma companies that will need this functional structural biology and disease research tool. So we think that it's a great start for that product line. But of course, we don't expect that in revenue this year, that will take a while.

Got it. Okay. All right. Thank you.

The next question comes from Brandon Couillard of Jefferies. Please go ahead.

Hey, thanks. Good afternoon. Frank, on the timsTOF platform, I appreciate the update on the installed base and revenue ramp looks like you've already placed 75 systems in the first half of the year. Just curious, if you could speak to the new HT introduction and whether that system will appeal to a broader customer base and then update us on where you think the installed base could ultimately go for the timsTOF platform, let's say, over the next two, three years?

Okay. Well, thank you, Brandon. So the timsTOF HT in part will -- that's -- the timsTOF Pro, some of those orders in the future will be timsTOF HT orders. So that's not purely additive. But -- so it's a further strengthening of the product line. I think it's particularly high throughput customers and particularly plasma proteomics customers will find the HT even more powerful and robust in all of that and even higher dynamic range. So particularly for plasma proteomics or for liquid biopsy research, for cancer biomarkers, for anybody who pursues a multiomic strategy, I think it's all going to be quite attractive. So it's yet another building block just pushing the flywheel again to add additional capabilities to our broader and broader timsTOF platform. Your observations about numbers of units shipped, therefore, in the first half or put into revenue is correct. And we expect that product line to ramp further. I mean, it continues to be, obviously, a double-digit growth product line for us. And even here, due to some supply chain issues, our order performance is even higher than our revenue performance. So this is all very much on track and we continue to bring out new workflows, new software. As you know, we invested in companies and investments to also add a lot more consumables and sample prep automation. That will take a little bit of time until that gets developed and gets rolled out, but it gets us becomes a broader and proteomics.

And a follow-up really for Gerald. Can you just clarify, so the FX headwind on the topline, is that actually an incremental tailwind to full year margins? Just help us understand the impact of currency on the OPM line for the year. Thanks.

Yes. Sure, Brandon. Just generally speaking, the way it works for us, especially when the US dollar strengthens as it has in this particular quarter quite strongly. We end up with a headwind on the revenue line, as you've described, and we end up with a tailwind in both gross margin and operating margin. By the time you net those and get down to the EPS line, it's pretty near neutral. And that's -- we have seen some favorability actually in the second quarter. But fundamentally, we get variability quarter-by-quarter as a result of these movements. And just I think you likely know this, Brandon, but it's not only USD against Euro or Franc, we have -- we also have a lot of variability against the other currencies. So it's complicated, but that's generally the big picture.

In addition to that, we have -- this year, we have a headwind from inflation and logistics costs, while pricing actions have been put into place for Bruker, they take a while, because we have the high backlog and so on. So we have a net headwind of maybe -- for the full year, maybe estimating 20 to 30 bps between inflation headwind that could be up to up to 100 bps and an FX tailwind on margins that is maybe more for the full year, more in the 60 to 70 bps range. So it's partially offsetting, but it's a net headwind to margins this year.

Great. Thanks.

You're welcome.

The next question is from Jack Meehan of Nephron Research. Please go ahead.

Thanks. Good afternoon. I wanted to start just on CALID. You talked about some of the supply chain constraints in the quarter. Is it just possible to quantify what the revenue impact might have been? My back of the envelope was something like $5 million to $10 million. I don't know if that's a good ballpark or not?

For Bruker, it was -- for Bruker overall, not for CALID -- I'm not -- we don't want to break it up into groups, but it was -- we don't want to quantify it, because then it's almost like a separate set of books, what would everything have been, had you had more revenue. But we had revenue delays from Q2 into Q3, and we'll have more from Q3 into Q4, and it's tens of millions. Obviously not high tens of millions. So it's meaningful. And we think that will be kind of an effect that we'll have in Q3 and probably again in Q4 until that sorts itself out. I think that's going to be next year. Nonetheless, with all of that in, we still have, obviously, a good organic growth rate. But that's why our book-to-bill is so high and our backlog is so strong, because we have some revenue delays of tens of millions of dollars from quarter to quarter. And that's entirely supply chain and logistics, and every once in a while, a customer site isn't quite ready, but that we always have. So it's not demand, which is good. It's not -- certainly not competitiveness. We're doing extremely well, but it is supply chain and logistics. I mean there is a certain amount of disarray and that continues. I wouldn't call it disruption, that's still strong, but the disarray is still there, and it's challenging.

Yes, it makes sense. And then I wanted to talk about MALDI. So coming out of AACC, one of the big themes I was hearing is just automation, given staff shortages. I was wondering how you think this is going to play out in the microbiology lab and just how the instrument placements for MALDI are trending this year? I know you talked about over 600 last year. Is it possible to talk about just where they're going to land this year?

It's a little early in the year, obviously. We -- so I don't know what it will be by the end of the year. Last year, we had exceptionally strong unit growth, this year that will be not as strong. Also, we had -- last year, we had some MALDI Biotyper business into Russia. So that's not going to be happen this year. Obviously, there's no business there. And we already -- we launched for Europe at least, at ECCMID some further MALDI automation solutions that we've developed with our subsidiary in the Czech Republic for MALDI automation. And there are more other workflows that are going to be more and more automated. So far, that field is only partially automated and a lot of it is manual that has been the standard, but we absolutely agree that the trend is towards more at least semi automation. One doesn't always need $1 million sample-to-answer automation, most less, don't look for that. But some of the more laborious and repetitive steps, if they can be automated, we have some solutions, although you almost have to get regulatory approval. So some of those have now been launched for Europe with regulatory approval. We'll look forward to the regulatory approval in other markets eventually. And then, of course, more is in the pipeline. So basically, we agree with the trend, and we're responding to that. We're not only improving assays and software and the instruments, although the instrument is really best-in-class, but also the automation availability and capabilities of the automation solutions to support it just as we do in proteomics. Development these days and more to come.

The next question is from Josh Waldman of Cleveland Research. Please go ahead.

Hey, guys. Thanks for taking my questions. Frank, the deck noted supply chain constraints have been in optics and commenting on CALID. What about the rest of the business? Have you seen areas of sequential improvement? I guess when we look at the second half implied guide, it seems to be conservative given the comps we are using. We have pricing coming in. Is it largely a supply chain that's kind of giving you -- leading you to be more prudent in the guide, do you think?

Absolutely. That's exactly that. And nobody is immune to supply chain. It's -- we haven't mentioned it, but it's basically every division is playing wakamo with problems that keep coming up. And we have more inventory buffers and things like that. But that only goes so far. So we're all -- I mean I think our teams are really managing extremely well. But yes, I mean, in the Bruker Optics and invest, there were some more issues. And it's always just delays really, but delays -- but it's not only where we mentioned it. I would say it's pervasive and affects all businesses that use electronics or even other materials. And so far, I would not say that it is getting better yet. So we're not saying that -- we're not seeing that yet. And so we think it will certainly last until the end of the year and go into early next year, which is why we are more -- why we're also being prudent. We -- without supply chain limitations, we could do more backlog conversion this year. But this -- and we think we'll have a good second half of the year, but some of that will still also good thing perhaps to also have good backlog going into 2023. But some of that is not only by choice, but really by supply chain limitations.

Got it. And Gerald, I wondered if you could talk through how cost in the second quarter materialized versus your expectations and how you're thinking about margin progression through the remainder of the year?

I'm sorry, I didn't hear your earlier part of your question? Can you just repeat it?

Yes. I wondered if you could comment on how costs in the second quarter materialized versus your expectations picking mainly, but maybe OpEx as well?

Sure, so I think generally speaking, we -- as you may recall, Josh, we communicated in the first quarter earnings call that we were expecting to have our OpEx, for example, outpace our revenue in the second quarter, and that's essentially how it played out. We still delivered solid EPS performance and EPS consensus in the quarter. But fundamentally, we are investing heavily, I would say, in some of our important Project Accelerate 2.0 initiatives. And you saw that, I think, in the sales and marketing line, certainly in the R&D line in the second quarter. I would also say in terms of inflation cost pressures, we did see that as well. I think, generally speaking, our teams handled that well, especially with some of the supply chain issues that you just heard Frank describing. So I think overall, I'm very, very pleased with how the cost management occurred in the second quarter, and we're going to have to deliver something similar, I think, in the third quarter. And then obviously, as you probably have heard, we expect the third quarter to be a little dampened by supply chain issues, which just means the fourth quarter is going to be larger.

All right. Appreciate it.

Sure.

The next question comes from Max Masucci of Cowen. Please go ahead.

Thanks for taking the questions. In light of Perkins business divestitures earlier this week, do you see potential to pursue a similar sort of Perkin type divestiture strategy? Or do you feel like you've already executed on that strategy and covered the bases under Project Accelerate 1.0 and 2.0?

Yes. Even earlier, Max, no, we're not planning any divestitures. We're very happy with our big businesses. And obviously, there are some areas where we're disproportionately investing, which is fine. But we don't really have any legacy business. We have core businesses and everything we have is core business and some areas we particularly try to grow with high-margin opportunities in new fields, in spatial biology, proteomics, et cetera. So no, that's not a topic for us. And yes, we did do some pruning even before Project Accelerate 1.0, more around the 2012 to '15 time frame. We did some pruning. It wasn't large-scale divestitures as in this particular example that you've cited, but we did some pruning. We did some smaller divestitures and there are some product and business lines that we didn't continue or stopped investing in. But since then, I think what we have looks really quite healthy and many of our core businesses are -- have done very well last year, continue to do quite well. Of course, Projects Accelerate, it's a little bit where the glory is. And of course, that helps pull up our gross margins and accelerate growth. That formula is all working. But it only is working, because we have a very strong core business that's fundamentally technologically also core to a lot of the Project Accelerate. If we didn't have a base multi-top business we wouldn't be in microbiology. And there are many other examples that I could side. So our businesses are good and we're not looking at that. I think we have a good mix of core and Project Accelerate.

Got it. One more for me. You called out the continued pace of proactive investment in the Commercial and operational teams supporting Project Accelerate 2.0. Like can you give us some additional detail just around where you're making headcount adds and just your general approach towards building out your Commercial presence for some of the newer proteomics metabolomics and spatial offerings that might require a slightly more specialized sales approach?

You named them. So it is proteomics. There's different -- many different flavors of proteomics by now. Metabolomics lipidomics those are closely related. Then of course, spatial biology in C2 spatial biology with the Canopy investment. Acuity that's not going to have any product still next year but that's an ongoing investment. And yes we also have with the Optimal acquisition and additional investments in software and also Commercial capabilities we're investing also quite a bit into biopharma. So those are the -- proteomics multiomics spatial biology and biopharma that's where we have the most investments also on the Commercial side marketing selling specialized sales teams application support all that good stuff. And it's really working well for us. That's why I think -- it's the products but it's also I think in parallel developing the Commercial infrastructure to then leverage those products. I think we have the right mix right now but certainly continue to invest. I think this makes complete sense for us and I think we can deliver our EPS and margin commitments. So we're really trying to do both and we're able to do both.

Great. Thanks a lot.

Thank you, Max.

The next question is from Rachel Vatnsdal of JPMorgan. Please go ahead.

Hi. Thanks for taking the question. So first up on Europe that region grew low single digits this quarter. So can you walk us through what you're seeing in that market specifically on the funding and academic and government in light of some of these recessionary concerns? And then what do you expect Europe to really be able to grow this year?

I'm sorry what particular area were you focused on? We missed that part Rachel?

Yes. So the low single digits in Europe this quarter. I was just wondering if you can walk us through what you're seeing from a funding environment for academic and government specifically in Europe? And then, what are you anticipating for Europe growth for the year?

We've cited what we've seen for growth. This year Europe is the slowest growing major geography other than rest of world. And that's sort of like we continue -- what we expected. We're not expecting that to change necessarily in the second half of the year. So where Europe is more in the low to mid-single digits presumably also for the year. Academic and government funding in Europe continues to be reasonably healthy. It tends to be more steady in the major economies of Central and Western Europe and it's not so much affected refugees or energy pricing or defense spending, it doesn't seem to interact so strongly with academic and government funding because those research commitments in Europe at the European level and also in the individual countries generally are really quite long term and they tend to be maintained.

The only other thing I'd add here Rachel is that the order bookings performance for Europe in this category of the segments you're describing was quite solid actually for the first half. So we're not -- we're experiencing good bookings growth in that area.

Great. And then a follow-up on some of your earlier comments around the assumptions for the back half of the year. You said that you're expecting mid-single-digit organic growth in 3Q in spite of the fact some of the supply chain pressures that you referenced, but that you'll be planning on making up for that in 4Q. However, it sounded like you're also anticipating some of the supply chain headwinds to continue into 2023. So, can you just clarify those supply chain comments and when you think they will really soften as a headwind? And then for 4Q, are you assuming any outside seasonality from 4Q budget flushes or any other thing that's driving that incremental strength in 4Q? Thank you.

Good question. Usually budget flush and things like that is something that doesn't affect Bruker very much maybe more if you're if you're more of a consumables company that tends to be more of an effect that they tend to discuss for us that's not as relevant. We often get good orders but then they often then get delivered three, six, nine months later. So that's less of an effect for us. Yes, we know we expect the supply chain and logistics delays to continue for the remainder of the year. And nonetheless you do the math. We -- Q4 looks stronger for us than Q3 even with all of that in. And so, I think that's why -- that's how it adds up to our full year guidance that we've -- as you've seen that we've maintained certainly on organic growth and margins and EPS.

The next question is from Patrick Donnelly of Citi. Please go ahead.

Hi. This is Jason on for Patrick. Just one question for you. On inflation, you noted some pressure there. So I'm just curious what you're seeing more specifically across raw materials labor and freight sequentially? And is the second half still the right way to think about passing price due to some of those backlog dynamics? Thanks.

We're beginning to see more pricing improvements that are beginning to help us in the second half more than in the first half, but most of the pricing actions that we've taken at the beginning of the year and then again some of that in the middle of the year, most of that will help us next year. But we're getting a little bit of pricing -- little bit of pricing tailwind in the second half of the year, but it's still fairly modest certainly low single digits probably below 200 bps. The other question inflation on materials and logistics and labor. That's probably too granular for us to comment on. I mean obviously see some of those effects. You see effects everywhere. And yes I mean logistics there's probably some spiking costs there and some of that will come down. I don't think all of that will be permanent. Other areas remains to be seen.

This concludes our question-and-answer session. I would like to turn the conference back over to Justin Ward for closing remarks.

Thank you everyone for joining us today. Our leadership team looks forward to meeting with you at an event or speaking with you directly during the third quarter. Please feel free to reach out to me to arrange any follow-up. Have a great evening.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.